Editorial Comment

Treatment decision making in prostate cancer (PCa) is increasingly complex. Especially with numerous immunologic, chemotherapeutic, radiopharmaceutical, and hormonal treatment options approved by the Food and Drug Administration over the past few years, which makes issues of balancing treatment benefit, harms, and values difficult to assess.1 Castrate-resistant PCa can be treated with immunotherapy (sipuleucel-T), which involves genetically engineering immune cells, hormone therapy (abiraterone and enzalutamide), radiopharmaceuticals (radium-223), or chemotherapy (docetaxel or cabazitaxel).

Source: Urology - September 20, 2017 Category: Urology & Nephrology Authors: Zaina P. Qureshi, Oliver Sartor, Charles L. Bennett Source Type: research